Skip to main content
. 2022 Sep 10;56:102458. doi: 10.1016/j.redox.2022.102458

Fig. 7.

Fig. 7

PKM2 inhibitor suppresses HCC cells progression in vitro. (A) IP and Western blot analyses were performed to verify that Shikonin, could reducing the interaction between GTPBP4 and PKM2 proteins in GTPBP4 OE PLC/PRF/5 cells. n = 3. (B) Monomeric and dimeric PKM2 expression was analyzed using Western blot in GTPBP4 OE PLC/PRF/5 and control cells treated with or without Shikonin. n = 3. (C) The glucose-induce ECAR was determined in GTPBP4 OE PLC/PRF/5 and control cells treated with or without Shikonin. n = 6. one-way ANOVA. (D–E) Lactate production (D) and glucose consumption activity (E) were measured in GTPBP4 OE PLC/PRF/5 cells and GTPBP4 OE SMMC-7721 cells treated with or without Shikonin and their respective controls. n = 6. one-way ANOVA. (F) The migratory and invasive capacities of GTPBP4 OE PLC/PRF/5 cells treated with or without Shikonin and PLC/PRF/5 cells were evaluated by transwell assays. n = 6. one-way ANOVA (G) Cell proliferation of GTPBP4 OE PLC/PRF/5 cells treated with or without Shikonin and PLC/PRF/5 cells were assessed by CCK-8. n = 6. one-way ANOVA. (H) Apoptosis was assessed by flow cytometry in GTPBP4 OE PLC/PRF/5 cells treated with or without Shikonin and PLC/PRF/5 cells. n = 3, one-way ANOVA. Error bars represent the mean ± SD from three or more independent experiments. *P < 0.05, **P < 0.01, ***P < 0.001.